secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123411
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic Therapeutic Q3 net loss $17.7M; TX45 Phase 1b enrollment ahead; new HHT candidate TX2100
--------------------------------------------------------------------------------

- Net loss of $17.7M for Q3 2024 vs $10.1M a year ago; R&D spend $14.3M (up from $8.1M) on TX45 trials.
- Cash $159.1M as of Sept 30, 2024; runway into mid-2027 covering key readouts and HHT program.
- Phase 1b hemodynamic trial for TX45 enrollment ahead of plan; topline results expected late Q1 2025/early Q2 2025.
- First subject dosed in TX45 APEX Phase 2 trial in Oct 2024; topline data expected 2026.
- TX2100 development candidate selected for HHT (no approved therapy); Phase 1 trial expected Q4 2025/Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000095017024123411/0000950170-24-123411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000095017024123411/tecx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer